Drug intelligence / Profile preview

Yanlurukang

Development stage: Unknown
Lead developer: The Third Affiliated Hospital of Beijing University of Traditional Chinese Medicine
Administration: Oral

Overview

Yanlurukang is a Traditional Chinese Medicine (TCM) formulation, specifically developed as capsules for the treatment of mammary gland hyperplasia (breast hyperplasia). It is indicated for patients diagnosed with kidney Yang deficiency syndrome according to TCM principles. The drug is designed to alleviate breast pain and improve systemic TCM symptoms. It has been evaluated in clinical registry studies to monitor its effectiveness and safety in women aged 18 to 50 years.

Brand names: Yanlurukang
Other names: Yanlu rukang capsules

Beyond the preview

Go deeper on Yanlurukang.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Yanlurukang.

Explore the full profile